0.3734  0.003 (0.89%)		10-14 16:00
Open: 0.3787 High: 0.3787 Volume: 968,999		Pre. Close: 0.3701 Low: 0.34 Market Cap: 8(M)

Short term
Mid term
Targets	6-month :	0.45	1-year :	0.5
Resists	First :	0.38	Second :	0.43
Pivot price	0.37
Supports	First :	0.31	Second :	0.26
MAs	MA(5) :	0.38	MA(20) :	0.36
	MA(100) :	0.41	MA(250) :	0.69
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	49.9	D(3) :	64.1
RSI	RSI(14): 49.7
52-week	High :	1.29	Low :	0.21

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ADIL ] has closed above bottom band by 49.8%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.38 - 0.38	0.38 - 0.38
Low:	0.34 - 0.34	0.34 - 0.34
Close:	0.37 - 0.37	0.37 - 0.38

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Thu, 09 Oct 2025
Adial Pharmaceuticals Completes Analytical Validation of Cheek Swab Method for AD04 Genetic Testing in Alcohol Use Disorder Treatment - Quiver Quantitative

Thu, 09 Oct 2025
100% SNP concordance: Adial and Genomind validate cheek‑swab test for AD04; AG+ biomarker ~14% - Stock Titan

Tue, 30 Sep 2025
Maxim Group Upgrades Adial Pharmaceuticals (ADIL) - Nasdaq

Tue, 16 Sep 2025
Adial Pharmaceuticals Provides Business Update Following - GlobeNewswire

Wed, 03 Sep 2025
Adial Pharmaceuticals Granted a 180 Calendar Day Extension - GlobeNewswire

Mon, 01 Sep 2025
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	22 (M)
Shares Float	22 (M)
Held by Insiders	2.4 (%)
Held by Institutions	2.6 (%)
Shares Short	1,110 (K)
Shares Short P.Month	1,430 (K)

EPS	-0.71
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-88.4 %
Return on Equity (ttm)	-171.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.39
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.53
PEG Ratio	0
Price to Book value	1.43
Price to Sales	0
Price to Cash Flow	-1.26

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.